When a Biomarker Is Not Yet a Therapy

The central question is no longer whether TMAO is interesting. It is whether the evidence about TMAO and atrial fibrillation is strong enough to support treatment. The answer depends on keeping three claims separate: TMAO can be associated with AF in people, it can participate in the biological mechanisms that make AF more likely, and changing it can improve outcomes. The first claim has clinical support, the second has substantial preclinical support, and the third remains unproven in the evidence considered here.

That conclusion is not a compromise between enthusiasm and skepticism. It follows from the way the pathway behaves. TMAO is produced through several linked steps, measured in several different clinical settings, and cleared by a system that also affects cardiovascular risk. The number in a blood test is therefore a signal generated by a network, not a verdict delivered by one molecule. A credible judgment has to preserve the pathway, the atrial substrate, the clinical context, and the evidence level at the same time.

A molecule at the intersection of several routes

The pathway begins with dietary substrates such as choline, phosphatidylcholine, and L-carnitine. Gut microbes can convert these compounds to trimethylamine, or TMA. The host liver then oxidizes TMA through flavin monooxygenases, especially FMO3, to form TMAO. The kidneys help clear TMAO from the circulation. Each link can vary. Substrate availability can change; microbial composition and functional capacity can change; hepatic conversion can differ; renal clearance can fall. A measured TMAO level reflects the balance among these processes.

That architecture changes the meaning of the biomarker. A higher value may indicate greater microbial production, greater host conversion, reduced elimination, or a combination. It does not directly identify a particular bacterial species or prove that the measured concentration is the dominant cause of an AF event. Even the label “gut-derived” should be read carefully: the pathway begins in the gut, but the liver and kidney help determine what finally appears in blood.

The heart supplies another layer of variation. AF is not a single event with one biological cause. The atrium may already be structurally or electrically vulnerable; surgery may add an acute physiological stressor; established AF may create a different substrate from first-onset disease. A TMAO level measured before cardiac surgery is entering a different causal question from the same kind of measurement in a community cohort or before catheter-ablation follow-up. The metabolite does not change names across those settings, but the outcome and the surrounding physiology do.

This is why the clinical synthesis cannot be detached from the pathway. The 2026 systematic review retained 15 studies for qualitative synthesis and eight prospective estimates for its primary odds-ratio analysis. Higher versus lower circulating TMAO was associated with AF with a random-effects pooled odds ratio of 1.35, with a 95% confidence interval from 1.15 to 1.59. That finding supports a positive relationship across the included evidence. It does not define one concentration at which AF begins, provide an individual’s absolute probability, or show that lowering TMAO would reverse the association.

The heterogeneity is not incidental. The review reported I² of 68.3%, meaning that the study estimates varied substantially beyond what a common-effect interpretation would imply. The largest association appeared in postoperative AF after cardiac surgery, where one study reported an odds ratio of 2.88. Seven studies of spontaneous incident AF produced a pooled odds ratio of 1.31. In high-cardiovascular-risk and acute-HFpEF settings, estimates were null. These results can coexist if clinical setting modifies the contribution of TMAO, if the endpoint changes the biology being measured, or if other differences alter the signal.